Allakos Inc., which has deflected questions about its technology since its 2012 founding, continued to let its fundraising prowess do the talking after completing a $100 million series B to advance AK-002, a therapeutic antibody the company called its lead program, in disease areas ranging from gastrointestinal (GI) to dermatologic and ocular diseases.